20 April 2018 - Celltrion said Sunday it has recently won approval from the Australia's Therapeutic Goods Administration for the sale and marketing of Truxima, the Korean biopharmaceutical firm's cheaper biosimilar copy of Rituxan which was developed by Biogen and marketed by Roche.

Biosimilars are officially approved copycat medicines developed on patents of the original biopharmaceuticals when the patents expire. Truxima can be used for the treatment of various diseases, including rheumatoid arthritis and non-Hodgkin's lymphoma, a type of leukaemia.

Read Korea Times article